HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myozyme User Fee Goal Extended Until April

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme says the extension for the Pompe disease treatment is intended to provide the FDA time to review clarifying information.
Advertisement

Related Content

Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Genzyme Myozyme BLA For Pompe Disease Could Clear FDA By January
Genzyme Myozyme BLA For Pompe Disease Could Clear FDA By January

Topics

Advertisement
UsernamePublicRestriction

Register

PS063046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel